PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Scientists and plant breeders who are aiming to improve food production by improving photosynthesis in crop plants, would make a good choice if they chose to change the composition and concentration ...

"This was a pivotal trial in establishing the safety and efficacy of tenecteplase as an alternative to alteplase in the thrombolytic treatment of acute ischemic stroke within 4.5 hours in Asian ...

A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...

In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...

Genentech is informing its customers and distributors and is arranging for return of all impacted products. Genentech announced a voluntary recall of three lots of Activase (alteplase) 100mg vials ...

Background: Thrombolysis for acute ischemic stroke has remained controversial. The Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was conducted to assess the ...

LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...